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Abstract: 
Orthopedic surgeries have continued to increase, but the material of choice 
remains constant: titanium. Titanium has become the benchmark implant material due 
to its durability and non-immunogenic properties. However, while high rates of success 
are correlated with joint replacement surgery, certain patients with predisposed 
diseases such as diabetes or arthritis may have increased complications.1 This can be 
due to lack of osseointegration due to decreased bone formation and mineralization,2 
which will lead to increased rates of infection or aseptic loosening of the implant from 
the bone. 3 Current methods to alleviate these complications include invasive revisional 
surgeries, which can be emotionally taxing and dangerous towards the patient. 
Fortunately, new research has shown that bioactive peptides are able to modify titanium 
surfaces and mimic natural proteins to increase osseointegration.4 Previously, through 
solid phase peptide synthesis, a series of multivalent dendrons containing bioactive 
osteogenic growth peptide (OGP) domain and a titanium binding domain consisting of 
surface binding catechol groups were obtained. Dendrons containing 4 catechol units 
displayed increased binding strength to titanium oxide surfaces compared to the 2- and 
1-unit analogs.5 Titanium oxide functionalized with this peptide molecule and seeded 
with mouse calverial derived stem cells (MC3T3) showed up-regulation of osteogenic 
markers bone sialoprotein (BSP) and osteocalcin (OCN) by 3-fold and 60-fold relative to 
controls after 21 days. Furthermore, there was a 3-fold increase in calcium deposition.6 
These promising results suggest that these peptides may enhance bone regeneration in 
vivo. In this research, a study was performed in vivo to appraise this model and further 
apply it to other bioactive peptide mimics such as bone morphogenetic proteins (BMP) 
2, 7, and 9. Surgical Grade 5 titanium (Ti6Al4V) pins were coated with the peptide 
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molecules and implanted into Sprague Dawley Rat femurs. Biomechanical and 
histological analyses showed an increase in bone growth from a period of two to five 
weeks, which may indicate therapeutic benefits for these bioconjugates in diabetic 
animal models.  
Introduction: 
 Over the past twenty-years, total joint replacements have skyrocketed in the 
United States and by 2030, total hip and knee surgeries will reach an estimated four 
million procedures performed annually, which is a 601% increase from 2005.1 While the 
number of procedures may be growing, the material being used, titanium, has not 
changed. The requirement of an orthopaedic implant to function correctly is its ability to 
osseointegrate, which means achieving adequate bone growth around the implant.4,6 
Due to titanium’s durability and non-immunogenic properties, titanium has become 
known as the benchmark implant material. However, while high rates of success are 
correlated with joint replacement surgery, if osseointegration fails to take place and the 
implant becomes loose, this results in a failed surgery and many negative 
consequences. Micromotions of this loose implant will generate gaps between the bone 
and implant interface, which will significantly delay the healing process by causing 
infections2 or wear-particles induced osteolysis.3-4 Recent research has aimed to 
minimize these complications by focusing on biomaterials that employ bioactive 
peptides that are able to communicate with the body and promote a desired response of 
improving contact with bone.5  
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 As stated earlier, by acquiring fast osseointegration of the implant, this will 
decrease the amount of complications later on. One possible solution for increased 
early implant osseointegration is the surface modification of titanium implants. Surface 
modifications help to enhance the biocompatible and osteoconductive properties; 
leading to better osseointegration.6 Osteoconductive properties are modifications that 
allow for bone to grow on the surface and can be achieved by increasing the surface 
area and porosity at the surface of the implant7 or by using peptides that promote cell 
adhesion. However, there have been certain ways to promote early onset of bone 
growth via osteoinductive approaches using growth hormones such as Bone 
Morphogenetic Protein-2 (BMP-2),8 or by using zinc surface modifications.9 These 
approaches have shown promising results in vitro and in vivo.  
 The two most common bone forming growth factors are Osteogenic Growth 
Protein (OGP) and Bone Morphogenic Protein (BMP). BMP has started to become 
frequently used in orthopedic surgery and has been approved by the FDA for certain 
procedures such as anterior lumbar interbody fusion, open tibial shaft fractures, and 
recalcitrant long bone nonunions.1-2 Additionally, it has achieved relatively widespread 
off-label use in a number of operative settings which necessitate a bone fusion. 
Comparable to BMP, Osteogenic growth protein (OGP) has similar growth factor 
potential and can be used in practical applications within orthopedics. OGP can be 
found in micromolar concentrations in the human blood serum10 and has been found to 
enhance proliferation, differentiation, and matrix mineralization of osteoblasts.11 The 
active sequences of both OGP (YGFGG, 10-14) and various BMP molecules have 
shown success in bioactivity regarding orthopaedic implants. 
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 Recently, we have shown that bioactive molecules containing the short active 
peptide sequences attached to the PEG-Catechol binding domains are able to modify 
the titanium surface.5 A series of multivalent dendrons containing bioactive osteogenic 
growth peptide (OGP, 10-14) domain and four surface binding catechol groups were 
obtained. The catechol groups tethered to the titanium oxide surface via coordination 
bonds and it was shown that the peptide remained on the surface for up to 14 days in 
vitro. In addition, the two bone forming markers bone sialoprotein (BSP) and osteocalcin 
were upregulated 3-fold ad 60-fold. There was also an 3-fold increase in calcium 
deposition relative to controls. From these results, it showed that OGP (10-14) was 
bioactive and was an appropriate surface modification of titanium to enhance 
osteogenesis in vitro.  
For this study, Grade 5 titanium (Ti6Al4V) implants were coated multiple versions of the 
4-catechol unit dendron molecule bearing different bioactive peptide sequences (BMP 
2/7/9 and OGP). They were then implanted into Sprague Dawley rat femurs in order to 
assess the performance of the bioactive molecules in promoting bone growth. Non-
functionalized pins were also used in vivo as a control method. We hypothesize that 
when compared to the control, the four peptides will enhance osteoblastic 
differentiation, resulting in increased bone growth around the implant site.  
Materials and Methods: 
 The first goal of the project was to create and synthesize the bioactive peptide 
coating that would be used on the pins. In addition, the binding properties of this peptide 
dendrimer conjugate would have to be characterized for titanium functionalization. 
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Previously published by the Becker group5 were the steps needed to create the peptide 
dendrimer conjugate via Fmoc solid-phase peptide synthesis (SPPS) using a  
Liberty 1 peptide synthesizer (CEM Corporation, Matthews, NC). To start, 0.25 mmol of 
Fmoc- amino acid - Wang resin of the C-terminal amino acid of the peptide sequence 
was loaded into the synthesizer. For 
example, a Fmoc-Gly-Wang resin was used 
for the synthesis of OGP. The N-terminus of 
this amino acid was made available for amino acid addition via deprotection of the Fmoc 
group, which was done under microwave irradiation. The four conjugates created will be 
peptide mimics of OGP and BMP, which as discussed previously, are growth factors 
involved in bone morphogenesis. These peptide mimics will be the active sequences of 
OGP, BMP-2, BMP-7, and BMP-9 (see table). These have been shown to have high 
success with inducing bone morphogenesis and are more stable and easier to 
synthesize than the full native protein.  
Once created in the synthesizer, the resin with peptide sequence was transferred 
to a peptide synthesis reaction vessel for the remainder of the reactions. The 
synthesized peptide was then washed three times each by dimethylformamide (DMF), 
methanol (MeOH), and dichloromethane (DCM), and then swelled in dimethylformamide 
(DMF) for 15 minutes under argon bubbling. The terminal Fmoc group was deprotected 
using a 25 mL cocktail of a 20% Piperidine in DMF and Hydroxybenzotriazole (HOBt) 
solution for 1 hour. Afterwards, the deprotection solution was drained, and the resin was 
washed again using DMF, MeOH, and DCM. A solution of Fmoc-NH-PEG6-Propionic 
acid (4 equiv, 1 mmol) (AAPPTEC, Louisville, KY) in DMF was then added to the resin 
Peptide  Sequence 
OGP (10-14) YGFGG 
BMP-2 (73-92) KIPKASSVPTELSAISTLYL 
BMP-7 (89-117) TVPKPSSAPTQLNAISTLYF 
BMP-9 (68-87) KVGKASSVPTKLSPISILYK 
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along with a solution of HOBt (4 equiv, 1 mmol) (AAPPTEC, Louisville, KY) in DMF. To 
start the addition, Diisopropylcarbodiimide (DIC, 4 equiv, 1 mmol) was added. This 
coupling reaction was run for 3 hours to yield the peptide with six-repeat unit PEG 
spacer group.  
The next step involved the dendron coupling to the PEGylated short peptide 
sequence. Like previous steps, the terminal Fmoc group of the Pegylated peptide 
sequence was deprotected using a 25 mL cocktail of a 20% Piperidine in DMF and 
Hydroxybenzotriazole (HOBt) solution for 1 hour. Afterwards, the deprotection solution 
was drained, and the resin was washed 3x DMF, 3x MeOH, and 3x DCM. A solution of 
Fmoc-Lys(Fmoc)-OH (4 equiv, 1 mmol) (AAPPTEC, Louisville, KY) in DMF was added 
to the resin along with a solution of HOBt (4 equiv, 1 mmol) (AAPPTEC, Louisville, KY) 
in DMF. Two additions of lysine will occur in order to obtain the four-armed amine. To 
start the addition, Diisopropylcarbodiimide (DIC, 4 equiv, 1 mmol) was added. This 
coupling reaction was run for 4 hours total with the second addition of lysine occurring 
at the 2-hour timepoint to yield the bioconjugate containing four-armed lysine groups.  
Upon completion of this addition, the four Fmoc protecting groups of these lysine 
groups were deprotected using a 50 mL cocktail of a 20% Piperidine in DMF and 
Hydroxybenzotriazole (HOBt) solution for 1 hour. Afterwards, the deprotection solution 
was drained, and the resin was washed 3x DMF, 3x MeOH, and 3x DCM. A solution of 
acetal-protected 2,3 dihydroxyphenylpropionic acid (4 equiv, 1 mmol) (AAPPTEC, 
Louisville, KY) in DMF was added to the resin along with a solution of HOBt (4 equiv, 1 
mmol) (AAPPTEC, Louisville, KY) in DMF. To start the addition, 
Diisopropylcarbodiimide (DIC, 4 equiv, 1 mmol) was added and run for 3 hours.  
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Now that the bioconjugate was fully complete, acid cleavage and deprotection 
from the resin was performed by first washing with 3x DMF, 3x MeOH, and 3x DCM. 
Next, the cleavage cocktail was added to the resin, which consisted of 15 mL of 
trifluoracetic acid (TFA), 0.75 mL Triisopropylsilane (TIPS), and 0.75 mL H2O. This 
cleavage reaction was run for 2 hours total with a second identical aliquot of cocktail 
added at the 1-hour timepoint. Once complete, the solution was separated from the 
resin and the cleavage solution was removed under reduced pressure. After the peptide 
was obtained, it was redissolved in a small amount of TFA and then precipitated in cold 
diethyl ether three times. After being centrifuged, the precipitate was dried and dialyzed 
against 70% ethanol for one day. The product obtained was dissolved in DMF and 
further purified by a Waters 1525 HPLC system using an XBridge Peptide BEH C18 
Column (300Å, 5 μm, 10 mm X 250 mm). The gradient used was from 20-80% 
methanol with 0.1% TFA with a flow rate of 3.3 mL/min. Finally, the purified products 
were freeze dried and analyzed by MALDI mass spectrometry. The steps for synthesis 
of the peptide-PEG-(cat)4 molecules can be seen in figure 1.   
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Fluorescent analogs of these bioactive conjugates were also made by adding 
Fmoc-Lys(Mca)-OH (4 equiv, 1 mmol) (AnaSpec, Fremont, CA) to the N-terminus of the 
peptide sequence. The steps for synthesis were identical to the regular bioconjugates.  
To begin the animal studies, approval by the University of Akron Institutional 
Animal Care and Committee (IACUC) was acquired. Eighty-four, 11-week-old, 350-450 
gram Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) were used. All 
of the rats were housed in a climate-controlled room with set 12-hour dark and light 
cycles. In addition, there were two rats per cage, and each of them were given free 
access to food and water. Treatment of the animals strictly adhered to the IACUC 
protocols and no variance from the guidelines occurred.  
Two titanium implants were used per rat and placed in both femurs. 168 custom 
TiAl6V4 pins, measuring 3/64” (1.19 mm) in diameter and 3/16” (4.7625 mm) in length 
were used (United Titanium, Wooster, Ohio). At the top of the pin, a 1/64” hole (0.396 
mm) was drilled, which would be used later during mechanical pull tests. The titanium 
pins were then washed three times each with hexane, methanol, and water and then 
autoclave sterilized.  
After sterilization, the pins were ready to be coated with the specific peptide 
conjugate. A 50 μM solution of bioconjugate in DMSO (Pharmaceutical grade, Sigma 
Aldrich) was created, and the sterilized pins were immersed in 10 mL of this solution. 
The titanium pins were placed in this solution 12 hours before surgery and stirred 
overnight. Prior to the surgery, the pins were removed from solution, washed once with 
DMSO, and washed 3x with PBS without magnesium and calcium.  
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Now that the coated pins were ready, implantation of the pins into the rat femurs 
was set to occur. There were five total groups for the implants. The implants without the 
bioconjugate coating or non-functionalized titanium were used as controls. The other 
four functionalized implants were coated with OGP, BMP2, BMP7, and BMP9 based 
conjugates. Rats were anesthetized via intramuscular injection using a cocktail of 0.57 
mL/kg of ketamine (100 mg/mL): xylazine (20 mg/mL): acepromazine (10 mg/mL) 
(29.6:5.95:0.553). A subcutaneous injection of buprenorphine (0.02 mg/kg) was also 
applied for pain relief.  Once the rats were unconscious, bilateral lower extremities were 
shaved completely and prepped using Betadine®. On the operating table, the rat was 
draped in a sterile fashion with only the lower extremity of interest exposed. An 
orthopaedic surgeon from Summa Hospitals performed these surgeries with assistance, 
and both individuals followed strict sterilization techniques. To access the femur, a 
longitudinal incision was made along the mid-femur, and blunt dissection was carried 
down to bone. Once exposed, the surgeon drilled a 3/64” (1.19 mm) hole in the femur, 
and the specific titanium pin was inserted. Once the pin was inserted into the femur, it 
was made sure that it could not be easily removed or disturbed. The incision was then 
closed with 4-0 nylon sutures. As stated earlier, each rat received one pin in each 
femur, and total surgery time for one rat was about one hour. Post-operatively, the rats 
were placed in individual cages with heating mats underneath and kept under close 
supervision. Once fully awake, they were provided with food and water and were given 
two additional doses of buprenorphine (0.02 mg/kg) every 12 hours.  
Depending on the group, the rats were sacrificed at either two or five-week time 
periods. Sodium Pentobarbital solution (Fatal-Plus) was administered via intraperitoneal 
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injection followed by cutting of the diaphragm. The femurs were then harvested, cleared 
of any tissue, and stored in either 40% ethanol or 1x PBS at 4o C until use. The femurs 
stored in 40% ethanol were used for histological analysis and the femurs stored in 1x 
PBS were used for biomechanics. 
The bone samples used for histological analysis were analyzed using 
histomorphometric analysis using color thresholding. This was used in order to see 
bone remodeling over the two and 5-week time-points. The samples were stained with 
Sanderson’s rapid bone stain with Van Gieson counterstain. They were then imaged on 
a IX81 microscope (Olympus) and color thresholding was performed using the 
microimaging Olympus cellSens software. These images helped to analyze bone area 
(BA) and bone-to-implant contact (BIC).  BA was defined as the area percentage of the 
newly formed bone within an area 100 μm outside the implant to the whole area of 
interest. BIC was defined as the percentage of osseointegration on the implant. 
Bone-to-implant contact or bone growth around the implant was assessed using 
a biomechanical pull-out test. The pull-out force of each pin was measured by an 
Instron 5567 (Canton, MA). To start, the femurs were secured to a custom holding 
device that allowed to titanium pin to be exposed to the direction of the pulling-force. As 
stated earlier, there was a small hole in each implant. A 0.007-inch diameter piano wire 
was threaded through this hole and attached to a 100 N load cell on the Instron 
instrument. Once the sample were properly fixed, a 2 N pre-load was applied to ensure 
proper and identical wire tautness among implants. Once acquired, the pins were 
pulled-out at 2 mm/min until the implant failed or slipped from the bone. By determining 
the maximum force before failure in a load displacement curve (load vs extension), the 
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pullout force (N) was determined for the implants. The results for the five implant groups 
were then compared.  
The final step was analyzing the data acquired from the biomechanical and 
histological tests. Statistical analysis was performed using IBM SPSS Statistics 24 
(Armonk, New York).  The data that was presented as box-and-whisker plots showed 
only the median, quartiles, whiskers, and outliers. Before any of biomechanical data 
could be tested for significance, a log transformation was performed. Afterwards, a one-
way analysis of variance (ANOVA) following multiple comparisons with the Tukey-
Kramer method at 95.0% confidence level was performed to show which means were 
significantly different from each other. For the acquired histology data, no transformation 
was applied, and a one-way ANOVA was performed followed by multiple comparison 
with the Tukey-Kramer method at 95.0% confidence level.  
Results: 
In previous studies conducted by the Becker group, we have shown that the 
bioactive conjugate OGP-PEG-(Cat)4 was synthesized successfully using solid phase 
peptide synthesis (SPSS). This molecule was able to have distinct peptide and binding 
domains that retained their intended function. In this study, we further expanded this 
design by applying and using identical methods to synthesize short peptide mimics of 
bone morphogenetic proteins 2,7, and 9. These products were confirmed by Matrix-
assisted laser desorption/ionization (MALDI) mass spectroscopy and analytical HPLC.  
As mentioned earlier, the binding affinity of the bioconjugates to Grade 5 
Titanium (Ti6Al4V) was quantified using fluorescence spectroscopy. The same 
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molecular structure of the bioconjugates was used for the fluorescence studies, except 
there was an addition of a coumarin-containing lysine amino acid (Fmoc-NH-Lys(Mca)-
OH) to the N-terminus of the peptide sequence. After coating the titanium implants, the 
concentration of the solution was compared to the concentration of the original solution 
before coating. As a result, the implant surface concentration of the peptide 
bioconjugates were measured and analyzed by fluorescence. These results from figure 
2 showed that the surface concentration of the peptide bioconjugates were all relatively 
the same.   
 
 
 
 
 
The rats were sacrificed at the timepoints of two weeks and five weeks after the 
implantation of the titanium pins. Immediately following, implants were pulled out from 
the femurs. No statistical difference (p>0.05) was seen between the bioconjugate 
groups at two weeks. However, at five weeks, the Control and OGP groups were 
statistically higher than all the other groups at two and five weeks respectively. As noted 
earlier, the samples were preloaded with a 2N force to ensure identical wire tautness 
before the test. Some of the samples did fall out of the bone before the 2N force was 
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reached and this data was still included for the box plots and statistic calculations 
(Figure 3).  
Using light microscopy, we were able to visualize the contact been the titanium 
pin and the bone. Histology was analyzed in three ways: the whole pin-bone interface 
(femur-bone interface), the spongy-bone interface, and the cortical-bone interface. The 
femurs were stained using a Sanderson’s Rapid Bone stain with a Van Gieson 
counterstain, which stained mineralized bone pink and osteoid blue. Three cutting axes 
of the implant were also utilized (figure 4). By selecting certain regions of interest, the 
amount of bone formation around the implant was quantified (figure 5). Bone area (BA) 
was quantified by measuring the area of bone within a 100 µm and was represented as 
a percentage (figures 6-8). All samples were normalized by the area of the interface of 
interest. By analyzing the BA for the Spongy-bone, cortical-bone, and femur-bone 
interface, there was a correlated increase from 2 to 5 weeks, however, there were very 
few significant differences. When the control pin was compared to the other four peptide 
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mimics, there was not a significant amount of extra bone growth for the functionalized 
pins.   
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Discussion:  
 Previous results from our in vitro studies done with MC3T3’s showed promising 
results with increased bone formation and osteoblast differentiation. This established 
reason to apply these bioconjugates in vivo in a rat model. However, after 
biomechanical testing and histomorphometric analysis, results from this in vivo 
experiment suggest that the functionalized coating performs similarly to the uncoated, 
control pins.  
The biomechanical testing appeared to show no significantly promising results for 
the pin coatings. The uncoated, control pins and the OGP bioconjugate coating 
performed similarly with increased bone growth from two to five weeks. When the two 
groups were statistically compared, there was no significant differences at either 
timepoint, leading us to believe that something must have gone wrong due to the 
promising results from the in vitro study. As for the BMP coated samples, there was no 
significant bone growth from two to five weeks, which included the samples that fell out 
of the bone before the 2N preload force was applied. After five weeks recovery, it was 
not expected to have some of the pins not be anchored in the bone. Some possible 
speculations for these results could be that the coating itself was providing negative 
feedback to the surrounding tissue, resulting in decreased bone formation and 
anchorage around the implant. In addition, upon euthanasia of some of the rats, 
hematomas were found around the implants, which lead us to believe that the poor 
performance in vivo may be concentration dependent. It has been shown that high 
concentrations of Bone Morphogenetic Proteins, specifically BMP-2, can result in 
hematomas and ectopic bone formation. Analysis via a microarray could have been 
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done from the cells at the implant site. This would have helped to look at gene 
expression and the inflammatory response around the implant, which could have helped 
us better understand why the bioconjugate coatings did not perform as expected. 
Further analysis was needed to understand these unexpected results. 
Histological analysis yielded similar results to the biomechanical testing. The pins 
were cut along the short and long axes of the bone, while maintaining the long axis of 
the pins (see figure 4). Once cut, three different interfaces were assessed for the bone: 
the while pin-bone interface (femur-bone interface), the spongy or cancellous-bone 
interface, and the cortical-bone interface (ctb-pin) (see figure 4). These three different 
interfaces were then quantified for total bone growth around the interface. Bone volume 
percent for all three analyses yielded a trend of increased bone growth from two to five 
weeks, but with few significant differences (p<0.05). Further analysis using in vitro 
studies could help us to better understand these results.  
While the study yielded few significant differences between groups, it should be 
noted that these were done in healthy rats. As mentioned previously, titanium based 
joint replacement surgeries have a high rate of success, and a majority of failures were 
only seen in patients with predisposed conditions such as diabetes. Therefore, future 
work will be done with diabetic rat models to see if there are any clinical benefits in 
using these bioconjugates.  
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